Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A: NGM120 | Experimental | Single Dose |
|
| Part A: Placebo | Placebo Comparator | Single Dose |
|
| Part B: NGM120 | Experimental | Multiple Dose |
|
| Part B: Placebo | Placebo Comparator | Multiple Dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NGM120 | Biological | Subcutaneous Injection |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Part A Arm-Single Dose: Treatment Emergent Adverse events | Percentage of total subjects with Treatment Emergent Adverse event | 28 days |
| Part B Arm-Multiple Dose: Treatment Emergent Adverse events | Percentage of total subjects with Treatment Emergent Adverse event | 84 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nucleus Network Limited | Melbourne | Australia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002100 | Cachexia |
| ID | Term |
|---|---|
| D015431 | Weight Loss |
| D001836 | Body Weight Changes |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Other |
Subcutaneous Injection |
|
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D013851 | Thinness |